

Stockholm, Sweden

22 March 2017

## **Fourth member of Oncopeptides' Nomination Committee appointed for the 2017 AGM**

**Stockholm - March 22, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the composition of the Nomination Committee has now been completed.**

At the Extraordinary General Meeting October 26, 2016 it was resolved to establish a Nomination Committee according to principles laid down and in preparation for the AGM 2017. The Committee shall consist of four members representing the three largest shareholders, together with the Chairman of the Board.

At the end of 2016 the Nomination Committee consisted of Staffan Lindstrand (chairman) nominated by HealthCap VI L.P., Nina Rawal nominated by Industrifonden and Alan Hulme the Chairman of the Board.

The fourth member representing the third largest shareholder has been appointed subsequent to the company's shares being listed on Nasdaq Stockholm, which took place February 22, 2017. The company's third largest shareholder is GLADIATOR and will be represented on the Nomination Committee by Max Mitteregger.

The Nomination Committee's proposals will be presented in the Notice to the Annual General Meeting 2017 and on Oncopeptides' web site, [www.oncopeptides.se](http://www.oncopeptides.se).

### **For further information, please contact:**

Staffan Lindstrand, Chairman of the Nomination Committee of Oncopeptides AB, representing HealthCap VI L.P. E-mail: [staffan.lindstrand@healthcap.eu](mailto:staffan.lindstrand@healthcap.eu)

The information was submitted for publication at 16.00 CET on 22 March 2017.

### **About Oncopeptides**

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the Company in 2000, the Company has focused primarily on the development of the lead product candidate Ygalo, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of blood-based cancer diseases, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Visit [www.oncopeptides.se](http://www.oncopeptides.se) for more information.